Entrinsic Bioscience

What Entrinsic Bioscience does

Entrinsic Bioscience is a Norwood, Massachusetts-based ingredient biotechnology company that develops amino acid and peptide-based functional ingredients and APIs for food, beverage, nutrition, and medical food applications. The company's core technology is a proprietary biomapping and electrophysiology platform that maps dysregulated proteins to disease states and then identifies precise 2-9 amino acid combinations capable of selectively restoring protein function. This discovery engine is protected by 43 global issued patents and 44 pending applications across 12 patent families, covering 362,880 amino acid combinations, with an exclusive license to US Patent 10,322,109 from the University of Florida Research Foundation. Technology originated from a $40 million NASA/BARDA/NIH grant to address astronaut GI toxicity from ionizing radiation, and the platform has been validated through 13 clinical and preclinical trials and 13 peer-reviewed publications.

Entrinsic's commercial portfolio centers on the enterade medical food brand: enterade Advanced Oncology Formula, launched in 2018 to reduce GI side effects of chemotherapy, radiation, and immunotherapy, and enterade IBS-D, launched in February 2023 for Irritable Bowel Syndrome with Diarrhea. The company has signaled expansion into sports and recreational rehydration beverages (October 2023 announcement) and is exploring dermatology applications following the April 2021 appointment of a senior dermatology consultant.

Revenue is generated through two complementary streams: direct-to-consumer sales of enterade products via enterade.com, and B2B platform licensing to global beverage and consumer goods companies, monetized through upfront fees, milestone payments, and royalties. Flagship B2B agreements include an exclusive global product development and testing deal with a large global beverage company and an exclusive consumer testing agreement with the world's largest consumer goods company, both focused on functional beverages and active aging hydration. Entrinsic is a privately held company founded in 2014/2015 with 11-50 employees, backed by EIP, NLDK, Johnson & Johnson Innovation | JJDC, and JUNO at the equity level, with Jefferies Funding providing $49 million in non-dilutive debt financing in 2021.

Name

Entrinsic Bioscience

Legal name

Entrinsic Bioscience

Website

https://entrinsicbioscience.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Entrinsic Bioscience is a Norwood, MA-based ingredient biotechnology company that uses a proprietary biomapping and electrophysiology platform to identify patented amino acid combinations for food, beverage, nutrition, and medical food applications, serving oncology and GI patients via enterade and global beverage and consumer goods companies via B2B licensing.

Ownership category

akta.pro rank

Product category

Medical Food and Functional Ingredient Biotechnology

NAICS

Food Manufacturing (311)

SIC

Medicinal Chemicals & Botanical Products (2833), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

akta.pro secondary industry

Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements) (AFAFAFAJ)

Keywords

• Amino acid formulations
• Medical food products
• Functional beverage ingredients
• Protein modulation platform
• Biomapping technology

Headquarters

HQ city

Norwood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Product Sales - enterade: Direct-to-consumer sales of enterade Advanced Oncology Formula, a medical food for cancer patients undergoing therapy. Also includes enterade IBS-D product line.
2. B2B Licensing & Partnerships: Monetization from upfront fees, milestone payments, and royalties through partnerships with global beverage and consumer goods companies for product development and testing.
3. Platform Licensing: Licensing of proprietary amino acid formulations to commercial partners for development of functional beverages and consumer health products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Entrinsic Bioscience develops and commercializes proprietary amino acid and peptide-based ingredient solutions using a biomapping and electrophysiology discovery platform. Its primary commercial offerings are the enterade line of medical food products (enterade Advanced Oncology Formula for cancer therapy supportive care, and enterade IBS-D for irritable bowel syndrome with diarrhea), sold directly to consumers through enterade.com, alongside B2B licensing of its patented amino acid formulations to global beverage and consumer goods companies for development of functional beverages and consumer health products.

Product overview

Entrinsic Bioscience offers a proprietary biomapping and electrophysiology discovery platform that identifies precise combinations of amino acids as functional ingredients and APIs. The company's commercial portfolio centers on enterade®, a medical food product line including enterade® Advanced Oncology Formula (for cancer therapy supportive care) and enterade® IBS-D (for irritable bowel syndrome). The platform is protected by 43 global issued patents covering 362,880 amino acid combinations, and has demonstrated efficacy across 13 clinical and preclinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• enterade: Medical food designed for supportive care for patients undergoing Cancer Therapy and Treatments (Chemotherapy, Radiation Therapy, Immunotherapy, etc.), as well as patients with chronic GI diseases (such as Crohn's, Colitis, Celiac). First patented, science-based product using combinations of amino acids clinically proven to reduce side effects of cancer treatment.

Products and services

• enterade Advanced Oncology Formula Medical food designed for supportive care of patients undergoing cancer therapy (chemotherapy, radiation, immunotherapy, stem cell transplantation). Clinically proven to reduce side effects including diarrhea, nausea, weight loss, dehydration, and malaise using patented amino acid combinations, sold direct-to-consumer via enterade.com.
• enterade IBS-D Dietary support product specifically formulated for patients with Irritable Bowel Syndrome with Diarrhea (IBS-D), leveraging the same proprietary amino acid cell signaling technology as enterade Advanced Oncology Formula, sold direct-to-consumer.
• Amino Acid Formulation Licensing (Beverage & Consumer Health) B2B licensing of Entrinsic's proprietary amino acid formulations and biomapping-derived ingredient solutions to global beverage and consumer goods companies for development of functional beverages, hydration products, and consumer health applications. Monetized through upfront fees, milestone payments, and royalties under exclusive global product development and testing agreements.

Quantifiable outcome

• 34% faster absorption than Pedialyte in SPIP ex vivo model
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered flagship, core, major and minor.

• Large Global Beverage CompanyflagshipStrategic or Co-development Partner · 1 January 2020Exclusive global product development and testing agreement for functional beverages. Beverage deal closed in 2020 with monetization from upfront fees, milestone payments, and royalties.
• University of Florida Research FoundationcoreStrategic or Co-development PartnerExclusive license to US Patent 10,322,109 encompassing compositions comprising combinations of 2-9 amino acids. Multiple collaborative research programs including NASA/BARDA grant work.
• Dana-Farber Cancer InstitutemajorStrategic or Co-development PartnerPhase 2, Double-Blinded, Randomized clinical study with proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation for Multiple Myeloma and Non-Hodgkin lymphoma.
• Brigham & Women's HospitalmajorStrategic or Co-development PartnerPilot study launched in 2018 in patients with inflammatory bowel disease (IBD) to evaluate amino acid-based solution efficacy.
• Markey Cancer Center (University of Kentucky)majorStrategic or Co-development PartnerPhase II study for neuroendocrine tumor patients with quality of life-limiting diarrhea. Multiple collaborative clinical studies including ASCO Annual Meeting publications.
• World's Largest Consumer Goods CompanyflagshipStrategic or Co-development PartnerExclusive consumer testing agreement focused on adult category for active aging and hydration applications.
• Penn State UniversityminorStrategic or Co-development PartnerMultiple research studies on beverage hydration index in healthy older adults and age-related differences in water and sodium handling following hydration beverage ingestion.
• Dr. Jerrold TurnerminorStrategic or Co-development PartnerRenowned barrier function expert appointed as Scientific Advisor in September 2020 to accelerate GI health program development.
• Dr. Apostolos PappasminorStrategic or Co-development PartnerInternationally renowned skin expert joined as Senior Dermatology Consultant in April 2021 to accelerate work on world's first natural anti-wrinkle formula.
• Dr. Olivier FontaineminorStrategic or Co-development PartnerWorld Health Organization's Medical Officer in the Diarrheal Diseases Control Programme joined Scientific Advisory Board in June 2015.
• USARIEM (U.S. Army Research Institute of Environmental Medicine)minorStrategic or Co-development PartnerResearch studies on enterade rehydration kinetics, exertional heat stroke mitigation, and comparison of oral rehydration therapy goals.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• PepsiCo: Owner of Gatorade and Propel, the dominant sports and functional hydration brands; sets the competitive bar for Entrinsic's beverage hydration claims and is plausibly the unnamed 'global beverage' partner.
• Abbott Laboratories: Global healthcare and nutrition company whose Pedialyte and Ensure medical nutrition lines compete head-to-head with enterade in clinical rehydration and oncology supportive care, while its established regulatory and distribution infrastructure dwarfs Entrinsic's.
• Nestlé Health Science: Operates the leading medical food portfolio (Peptamen, Impact) targeting oncology and GI patients, directly overlapping with Entrinsic's enterade oncology and IBS-D franchises and providing a strategic M&A benchmark.
• Herbalife Nutrition: Global direct-selling nutrition company with an extensive amino acid and meal replacement range, providing a comparable go-to-market and customer education template for Entrinsic's amino acid positioning.
• DSM-Firmenich: Global ingredients giant with a large bioactive peptide and amino acid portfolio; relevant peer because it both supplies and competes with amino-acid functional ingredient platforms like Entrinsic's.

Direct peers

• Standard Process: Whole-food and amino-acid based nutritional supplement company selling through practitioners and direct channels, comparable to Entrinsic's enterade medical food distribution and amino acid-centric product philosophy.
• Liquid I.V. Hydration multiplier brand competing on BHI-style performance claims with a similar consumer and active-aging target market, making it the most direct functional hydration comparable to EBS-MH.
• Thorne HealthTech: Premium supplement brand with deep clinical validation and practitioner channel, similar to Entrinsic's positioning of clinically proven amino acid formulations for performance and recovery use cases.
• Hydralyte: Medical-grade oral rehydration brand competing directly with enterade on the diarrhea and dehydration indication, particularly for oncology and pediatric rehydration.

Emerging players

• BioTechne: Reagents and functional protein company whose protein-modulation focus and SAB-driven development model intersect with Entrinsic's biomapping platform for amino acid cell-signaling combinations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/EntrinsicHealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entrinsic Bioscience